Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Pater

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|October 1, 1988
Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapyD Osoba, C Erlichman, A R Willan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials GroupN Murray, P Coy, J L Pater, et al.
Current Oncology (Toronto, Ont.)|July 7, 2017
Linkage of clinical trial and administrative data: a survey of cancer patient preferencesA E Hay, Y W Leung, J L Pater, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1994
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancerP Coy, D I Hodson, N Murray, et al.
Lancet (London, England)|July 3, 1993
Polychemotherapy in advanced non small cell lung cancer: a meta-analysisP J Souquet, F Chauvin, J P Boissel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1988
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trialE Rapp, J L Pater, A Willan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancerL M Reyno, M J Egorin, R M Canetta, et al.
Seminars in Oncology|October 1, 1994
Modeling toxicity and response in carboplatin-based combination chemotherapyM J Egorin, L M Reyno, R M Canetta, et al.
Cancer Treatment Reports|March 1, 1987
Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatinJ L Pater, J A Carmichael, G V Krepart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials GroupI C Quirt, W E Shelley, J L Pater, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|October 1, 1988
Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapyD Osoba, C Erlichman, A R Willan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials GroupN Murray, P Coy, J L Pater, et al.
Current Oncology (Toronto, Ont.)|July 7, 2017
Linkage of clinical trial and administrative data: a survey of cancer patient preferencesA E Hay, Y W Leung, J L Pater, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1994
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancerP Coy, D I Hodson, N Murray, et al.
Lancet (London, England)|July 3, 1993
Polychemotherapy in advanced non small cell lung cancer: a meta-analysisP J Souquet, F Chauvin, J P Boissel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1988
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trialE Rapp, J L Pater, A Willan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancerL M Reyno, M J Egorin, R M Canetta, et al.
Seminars in Oncology|October 1, 1994
Modeling toxicity and response in carboplatin-based combination chemotherapyM J Egorin, L M Reyno, R M Canetta, et al.
Cancer Treatment Reports|March 1, 1987
Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatinJ L Pater, J A Carmichael, G V Krepart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials GroupI C Quirt, W E Shelley, J L Pater, et al.
Pageof 7